Fracture prevention efforts should be considered in patients with CKD of any age, according to investigators.
Tenapanor is a first-in-class oral medication that works by blocking the NHE3 transporter in the gastrointestinal tract.
Elevated serum phosphate concentration may be associated with an increased risk for major adverse limb events in patients undergoing hemodialysis.
A study of stable dialysis patients receiving sucroferric oxyhydroxide found no significant changes in hemoglobin, ferritin level, and transferrin saturation.
Achieving serum phosphate levels of 3.5 to 4.5 mg/dL vs 5.0 to 6.0 mg/dL in patients on hemodialysis was associated with less coronary artery calcification, study findings suggest.
In a study of hospitalized patients, increased serum phosphate levels significant increased the risk of acute kidney injury, end-stage renal disease, and death.
In a study of hemodialysis patients, PAD risk increased nonlinearly with serum phosphate level.
By blocking paracellular phosphate transport, tenapanor added to phosphate binders may improve the hyperphosphatemia management in patients on maintenance dialysis, a study found.
In a study, elevated FGF23 was associated with increased risks of major adverse cardiovascular events and mortality in type 2 diabetes patients with normal or mildly impaired kidney function.
If confirmed, findings from 2 new studies would have important clinical implications for phosphate intake in the general population.